not effect either CI-V expression or CI activity. In contrast, earlyonset hypoxia decreased expression of CI (49%) and CII (40%). CIII-V changes were not significant (Fig.1A) . CI activity in early hypoxia increased 48% compared to normoxia controls (Fig.1B) . CONCLUSION: The impact of hypoxia on mitochondrial respiratory chain function in the fetal forebrain varied with the gestational age of exposure. Early exposure to significant hypoxia produced an enduring deficit in mitochondrial function exemplified by disruption of CI/II expression and dysregulation of CI activity. This likely mediates ongoing electron leakage, the base cause of oxidative stress, and ongoing brain injury.
108 Molecular similarities and dissimilarities between hellp syndrome and preeclampsia (PE) using shotgun and targeted proteomics OBJECTIVE: Although clinical management of HELLP syndrome is similar to PE, hypertension and proteinuria do not always occur with HELPP. Thus, it was suggested that HELLP and PE could be separate clinical entities. Based on the ability of the urine misfolded proteins to retain Congo red (congophilia) it was suggested PE is a protein conformational disorder similar to Alzheimer's disease. Molecular diagnostics are becoming more often part of modern clinical medicine. Here we used state of the art shotgun proteomics and targeted multiple reaction monitoring (MRM) mass spectrometry to discover and validate molecular signatures in crude urine samples of pregnant women with PE and HELLP that potentially differentiate between these two clinical conditions.
STUDY DESIGN:
We analyzed urine samples from six groups of patients classified phenotypically as: non-hypertensive healthy controls (CRL, n¼9, 30AE1 wks), women with idiopathic proteinuria (IP, n¼15, 28AE2 wks), PE mild features (mPE, n¼16, 33AE1 wks), superimposed PE (spPE, n¼16, 31AE1 wks), PE severe features (sPE, n¼16, 32AE1 wks) and HELLP (n¼16, 29AE1 wks). In the discovery phase, urine proteins were enriched by CR precipitation and subjected to UPLC-tandem mass spectrometry. Linear discriminant analysis (LDA) was used to cluster clinical groups based on molecular signatures. We choose a non-parsimonious set of peptides that distinguished among clinical phenotypes and were suitable for targeted validation using MRM in crude urine samples. RESULTS: 1,747 molecular IDs were identified in CR precipitates. These merged into 690 protein groups that generated good separation among clinical phenotypes with a false discovery rate of 1.12% (Fig. A) . 21 key peptides were prioritized through pairwise comparison among groups (Wilkes Lambda MANOVA¼0.006, p-value of 3.6 x 10 -14 ) (Fig. B) . Based on a full MS/MS spectral library, 98 MRM transitions were generated. CLIC1 (oxidant sensor activated by misfolded proteins), ABHD14B (lipid metabolizing-enzyme) and b2-microglobulin were among the parent proteins to distinguish sPE from HELLP. Principal component analysis demonstrated that targeted proteome from raw urine represented CR precipitate well and closely correlated with clinical criteria. CONCLUSION: Based on molecular signatures, HELLP syndrome appears to be a different clinical entity from sPE. OBJECTIVE: Women with pre-eclampsia (PE) have placental ischemia, hypertension, intrauterine growth restriction, increased activated natural killer (NK) cells, and pro-inflammatory cytokines, such as tumor necrosis factor (TNFa). To study placental ischemia induced hypertension during pregnancy we use the reduced uterine perfusion pressure (RUPP) preclinical rat model of PE. Previous studies from our lab have shown that TNFa is elevated in RUPP rats and that blockade of TNFa via Etanercept, decreases TNFa and hypertension in RUPP rats. However, the effect of TNFa blockade on NK cells is unknown. NK cells are activated by inflammatory cytokines and are strongly associated with preterm labor, intrauterine growth restriction, spontaneous abortion, and PE during pregnancy. Moreover, TNFa blockade in pregnant women continuing treatment for autoimmune disorders is not affiliated with any adverse maternal or Oral Concurrent 9 BASIC SCIENCE 2 ajog.org fetal outcomes. We hypothesize that Etanercept will decrease blood pressure and NK cell activation in RUPP rats. STUDY DESIGN: In this study, rats were divided into 3 groups: normal pregnant (NP) (n¼24), RUPP (n¼15), RUPP + Etanercept (0.4 mg/kg) (n¼11). On gestational day 14, RUPP surgery was performed and Etanercept was administered subcutaneously on gestational day 18. On day 19, conscious blood pressure (MAP), blood and placentas were collected. Flow cytometry was used for quantification of NK cells. RESULTS: MAP was elevated in RUPP vs. NP rats (117 AE 1 vs. 103 AE 1 mmHg, p<0.05). Importantly, Etanercept administration to RUPP rats reduced the MAP to 110 AE 2 (p<0.05 vs. RUPP rats). The increase in activated NK cells in both circulation (6.29 AE 2 vs. 3.76 AE 1. %) and the placenta (3.82 AE 1 vs. 2.06 AE 1%) of RUPP vs. NP rats decreased 3 fold in Etanercept treated RUPP rats (2.22 AE 1 vs. 6.29 AE 2 % gated, vs. RUPP) and (1.68 AE 1 vs. 3.82 AE 1% gated), respectively. No difference was observed between RUPP + Etanercept and NP circulating and placental activated NK cells. CONCLUSION: Etanercept treatment has beneficial effects by decreasing NK cells and significantly lowering blood pressure in response to placental ischemia. Therefore, Etanercept could be considered as a potential therapy to improve inflammation and hypertension during complicated pregnancies.
